Avadel Pharmaceuticals plc

$21.64+0.00%(+$0.00)
TickerSpark Score
68/100
Solid
30
Valuation
40
Profitability
100
Growth
68
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVDL research report →

52-Week Range89% of range
Low $6.38
Current $21.64
High $23.57

Companywww.avadel.com

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

CEO
Gregory J. Divis Jr.
IPO
1996
Employees
188
HQ
Dublin, IE

Price Chart

+140.71% · this period
$23.56$15.07$6.59Feb 13Aug 15Feb 13

Valuation

Market Cap
$2.12B
P/E
-7558.74
P/S
8.55
P/B
21.39
EV/EBITDA
205.48
Div Yield
0.00%

Profitability

Gross Margin
94.47%
Op Margin
1.82%
Net Margin
-0.11%
ROE
-0.33%
ROIC
0.28%

Growth & Income

Revenue
$169.12M · 504.79%
Net Income
$-48,832,000 · 69.53%
EPS
$-0.51 · 74.50%
Op Income
$-42,399,000
FCF YoY
63.50%

Performance & Tape

52W High
$23.57
52W Low
$6.38
50D MA
$21.50
200D MA
$15.49
Beta
1.31
Avg Volume
2.42M

Get TickerSpark's AI analysis on AVDL

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 13, 26Weiss Asset Management LPsell11,112,052
Feb 11, 26Weiss Asset Management LPother0
Feb 12, 26Rodriguez Susansell300,000
Feb 12, 26Thornton Peter J.sell42,000
Feb 12, 26Thornton Peter J.sell42,000
Feb 12, 26Thornton Peter J.sell11,000
Feb 12, 26Thornton Peter J.sell42,000
Feb 12, 26Thornton Peter J.sell115,060
Feb 12, 26Thornton Peter J.sell60,000
Feb 12, 26Thornton Peter J.sell33,000

Our AVDL Coverage

We haven't published any research on AVDL yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate AVDL Report →

Similar Companies